UX053 + Antipyretic + H2 Blocker + H1 Blocker
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type III
Conditions
Glycogen Storage Disease Type III
Trial Timeline
Oct 18, 2021 → Mar 20, 2023
NCT ID
NCT04990388About UX053 + Antipyretic + H2 Blocker + H1 Blocker
UX053 + Antipyretic + H2 Blocker + H1 Blocker is a phase 1/2 stage product being developed by Ultragenyx Pharmaceutical for Glycogen Storage Disease Type III. The current trial status is terminated. This product is registered under clinical trial identifier NCT04990388. Target conditions include Glycogen Storage Disease Type III.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04990388 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Glycogen Storage Disease Type III